EVQLV and Libera Bio are collaborating to develop and deliver new antibodies for intracellular cancer targets

EVQLV Inc. and Libera Bio SL have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent unmet medical needs.

  • Antibodies can be designed to engage very specific targets along cancer pathways
  • A lots of the best validated intracellular targets for cancer are considered “untreatable” because large molecules cannot spontaneously enter tumor cells.
  • EVQLV will design novel antibodies to address intracellular targets with high unmet needs
  • Libera Bio will use its MPN technology® to deliver these antibodies to their target

Multiple pathways within tumor cells, such as the MAPK pathway or the “hedgehog pathway”, can create the conditions for tumor development, growth and evasion of the immune system. Disrupting the signals in these pathways at one or more points can slow tumor growth and prevent their proliferation. Small molecules have been successfully developed for this purpose, but may present significant levels of toxicity and lack of specificity. Attempts have also been made to create antibodies that would force them into tumor cells, but this is a complex process, without success.

Libera Bio multifunctional polymer nanocapsules (MPN Technology®) offer an elegant way to deliver antibodies inside tumor cells. Relevant antibodies are encapsulated in nanocapsules made of natural polymers of approx. 1/10,000th of a millimeter in diameter. Nanocapsules protect antibodies or other biological drugs from degradation. Actively or passively targeted, MPNs deliver these biologics to intracellular targets. The second active ingredient can be co-encapsulated in the MPN and simultaneously delivered into the cytosol.

Whole antibodies, close to their natural form, can be delivered in this way. EVQLV has developed its own AI-based system to optimize the design of such antibodies. EVQLV will computationally generate and rapidly screen a large pool of diverse antibody candidates against a prioritized list of intracellular targets.

EVQLV and Libera Bio will jointly develop the new antibodies and their delivery to MPN, with the goal of offering them to larger pharmaceutical companies for late-stage development and commercialization.

“The combination of computational antibody design with Libera’s novel intracellular delivery technology allows us to overcome current antibody limitations, opening up a range of innovations for patients.” said Andrew Satz, co-founder and CEO of EVQLV. “We are thrilled to work alongside the team of experts at Libera Bio and continue our mission to accelerate the speed at which healing reaches those in need.”

“There are many intracellular targets that have so far been unreachable by conventional treatments and that can be effectively addressed by specially designed antibodies. We are thrilled to be working with EVQLV, who brings a strong background in molecular biology and state-of-the-art technology to design such novel antibodies. We look forward to creating new options for cancer patients with unmet needs,” added Olivier Jarry, co-founder and CEO of Libera Bio.

EVQLV (www.evqlv.com) is a privately held American company headquartered in New York and Miami. EVQLV uses advances in computing to revolutionize the design and development of therapeutic antibodies. EVQLV works with companies at all stages of antibody development, performing de novo antibody design, antibody optimization and designing the next generation of innovative immunotherapies.

Libera Bio SL (www.liberabio.com) is a private Spanish company, spun off from the University of Santiago de Compostela (Galicia, Spain). Libera Bio aims to change cancer therapy by allowing biologics to pass through the cell membrane and reach untreatable intracellular targets: the “Holy Grail” of oncology. She conducted preclinical studies of antibodies that deal with frequent mutations of KRAS, a protein involved in a large number of cancers, especially pancreatic, colon and lung cancer. It is now preparing for incentive studies with the goal of clinical trial approval.

Leave a Comment

Your email address will not be published. Required fields are marked *